氨丙吡酮 | 3690-04-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 氨丙吡酮
• 英文名称: aminopropylon
• 英文别名: N,N-dimethyl-DL-alanine 1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-ylamide；N,N-dimethyl-DL-alanine-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-ylamide)；N,N-Dimethyl-DL-alanin-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-ylamid)；N-(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)-2-(dimethylamino)-propanamide；N-(2,3-dihydro-1,5-dimethyl-3-oxo-2-phenyl-1H-pyrazol-4-yl)-2-(dimethylamino)propionamide；4-<2-Dimethylamino-propionylamino>-antipyrin；2-(dimethylamino)-N-(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)propanamide
• CAS: 3690-04-8
• 化学式: C₁₆H₂₂N₄O₂
• 分子量: 302.376
• InChiKey: UQNCVOXEVRELFR-UHFFFAOYSA-N

物化性质

• 熔点：
  181°
• 沸点：
  443.4°C (rough estimate)
• 密度：
  1.0777 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  55.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 储存条件：
  库房应保持通风、低温和干燥。

制备方法与用途

类别：有毒物品
毒性分级：中毒
急性毒性：口服-小鼠LD50: 2950 毫克/公斤；腹腔-小鼠LD50: 820 毫克/公斤
可燃性危险特性：可燃；燃烧时产生有毒氮氧化物烟雾
储运特性：库房通风、低温干燥
灭火剂：干粉、泡沫、砂土、二氧化碳、雾状水

反应信息

• 作为反应物：
  描述：

  氨丙吡酮 、 氘氧化钠 、 重水 生成 2-(dimethylamino)-N-[1-methyl-3-oxo-2-phenyl-5-(trideuteriomethyl)pyrazol-4-yl]propanamide
  参考文献：
  名称：

  GOROMARU T.; NODA A., CHEM. AND PHARM. BULL., 1978, 26, NO 7, 2258-2261

  摘要：

  DOI：
• 作为产物：
  描述：

  4-氨基安替比林 在 phosphorus pentoxide 、 苯 作用下， 生成 氨丙吡酮
  参考文献：
  名称：

  Takahashi et al., Yakugaku Zasshi/Journal of the Pharmaceutical Society of Japan, 1955, vol. 75, p. 1431,1432

  摘要：

  DOI：

文献信息

• CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTIC DELIVERY
  申请人：Cerulean Pharma Inc.

  公开号：US20130196906A1

  公开（公告）日：2013-08-01

  Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of a disease or disorder, e.g., autoimmune disease, inflammatory disease, central nervous system disorder, cardiovascular disease, or metabolic disorder. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.

  提供了关于使用CDP-治疗剂偶联物治疗疾病或紊乱的方法，例如自身免疫疾病、炎症性疾病、中枢神经系统紊乱、心血管疾病或代谢紊乱。还提供了CDP-治疗剂偶联物、包含CDP-治疗剂偶联物的颗粒以及包含CDP-治疗剂偶联物的组合物。
• COMPOSITIONS AND METHODS FOR TREATMENT OF AUTOIMMUNE AND OTHER DISEASE
  申请人：CERULEAN PHARMA INC.

  公开号：US20180193486A1

  公开（公告）日：2018-07-12

  Provided are methods relating to the use of CDP-therapeutic agent conjugates for the treatment of autoimmune disease, inflammatory disease, or cancer. Also provided are CDP-therapeutic agent conjugates, particles comprising CDP-therapeutic agent conjugates, and compositions comprising CDP-therapeutic agent conjugates.

  提供了关于使用CDP-治疗剂偶联物治疗自身免疫疾病、炎症性疾病或癌症的方法。还提供了CDP-治疗剂偶联物、包含CDP-治疗剂偶联物的颗粒以及包含CDP-治疗剂偶联物的组合物。
• PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1447401A1

  公开（公告）日：2004-08-18

  A piperidin-2-one derivative compound represented by formula (I): wherein all symbols are described in the specification, or a non-toxic salt thereof. The compound represented by formula (I) inhibits activation of p38MAP kinase, and is useful for prevention and/or treatment of various inflammatory diseases, rheumatoid arthritis, osteoarthritis, arthritis, osteoporosis, autoimmune diseases, infectious diseases, sepsis, cachexia, cerebral infarction, Alzheimer's disease, asthma, chronic pulmonary inflammatory diseases, reperfusion injury, thrombosis, glomerulonephritis, diabetes, graft versus host rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, tumor growth and metastasis, multiple myeloma, plasma cell leukemia, Castleman's disease, atrial myxoma, psoriasis, dermatitis, gout, adult respiratory distress syndrome (ARDS), arteriosclerosis, post-percutaneous transluminal coronary angioplasty (PTCA) restenosis or pancreatitis.

  一个由公式(I)表示的哌啶-2-酮衍生物化合物： 其中所有符号都在说明书中描述，或其无毒盐。 由公式(I)表示的化合物能抑制p38MAP激酶的激活，并且可用于预防或治疗各种炎症性疾病、类风湿性关节炎、骨关节炎、关节炎、骨质疏松症、自身免疫病、感染性疾病、败血症、恶病质、脑梗塞、阿尔茨海默病、哮喘、慢性肺泡炎、再灌注损伤、血栓形成、肾小球肾炎、糖尿病、移植物抗宿主病、炎症性肠病、克罗恩病、溃疡性结肠炎、多发性硬化症、肿瘤生长和转移、多发性骨髓瘤、浆细胞白血病、卡斯尔曼病、心房粘液瘤、银屑病、皮炎、痛风、成人呼吸窘迫综合征（ARDS）、动脉硬化、经皮腔内冠状动脉成形术（PTCA）后再狭窄或胰腺炎。
• Prodrugs containing novel bio-cleavable linkers
  申请人：Satyam Apparao

  公开号：US20060046967A1

  公开（公告）日：2006-03-02

  The invention provides the compounds of formula (I) or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one more of pharmaceutically acceptable carriers, vehicles or diluents. The invention further provides methods of preparation and methods of use of prodrugs including NO-releasing prodrugs, double prodrugs and mutual prodrugs comprising the compounds of formula I.

  本发明提供了公式(I)的化合物或其药用可接受的盐。本发明还提供了包含一个或多个公式I的化合物或其中间体以及一个或多个药用可接受的载体、车辆或稀释剂的药物组合物。本发明进一步提供了包括制备方法和使用方法在内的前药，包括释放一氧化氮的前药、双前药和相互前药，由公式I的化合物组成。
• Nitric Oxide Releasing Prodrugs of Therapeutic Agents
  申请人：SATYAM Apparao

  公开号：US20110263526A1

  公开（公告）日：2011-10-27

  The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.

  本发明涉及已知药物或治疗剂的一氧化氮释放前药，其在此处表示为式(I)的化合物，其中药物或治疗剂包含一个或多个功能基团，独立地选自羧酸、氨基、羟基和巯基。该发明还涉及制备一氧化氮释放前药（式(I)的化合物）的方法，含有它们的药物组合物以及使用这些前药的方法。